[Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial].

A N Boyko,O V Boyko,K Z Bakhtiyarova,E I Gusev,V A Dudin, L G Zaslavsky,N A Malkova,Ye V Parshina,I Ye Poverennova, S A Siverceva,N A Totolyan,S G Shchur,A S Fedulov,F A Khabirov,D D Bolsun,A V Zinkina-Orikhan,Yu N Linkova, T V Chernovskaya

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova（2022）

引用 3|浏览3

暂无评分

摘要

The new drug samPEG-IFN-β1a is an effective and safe agent for relapsing remitting multiple sclerosis treatment, while having an advantage over other low-dose interferons in the form of reduced frequency of intramuscular injections.

查看译文

关键词

DMT,RRMS,multiple sclerosis,pegylated interferon beta-1a,samPEG-IFN-β1a

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要